Cantargia’s Q122 results were in line with our expectations.
Redeye updates its view on Better Collective post its Q1-results which was in line with expectations...
Det råder hög efterfrågan på studentbostäder vilket gynnar fastighetsbolaget som fortsätter att expa...
While the Q1 report offered few surprises, the Novartis subset analysis of CANOPY-1 was an important...
BankNordik just raised its 2022 net profit guidance by 21% to DKK 160-190m from previously DKK 130-1...
Redeye comments on Cantargia's Q1 report 2022.
Intellego meddelade under fredagen den 20 maj att bolaget ingått ett LOI avseende att förvärva major...
Order från Google Fiber i USA fortsätter att utvecklas väl för InCoax del.
Bra resultat i Q1'22... AdderaCare rapporterade EBITDA på 6,2 mkr i Q1'22, vilket innebar en klar fö...
Leveranser till Nyttobostäder Nettoomsättningen i Q1'22 uppgick till 895 mkr (173 mkr i Q1'21), driv...
Redeye updates its view on Vicore following an eventful year for the company and its increasingly co...
Redeye lowers its estimates because of the slow Q1 and due to uncertainty about the big Russian orde...
This morning, Cantargia reported its Q1 numbers for 2022 with an operating loss of SEK 122m, 14% mor...
Investmentbolaget MTIs har utvecklats positivt trots senaste tiden som har kantats av omvärldsoro oc...
Redeye maintains the valuation of Kontigo Care at SEK 12 per share.
Impressive start to the year Positive revisions due to core business and M&A Three new promising gam...
‘22e ND/EBITDA of 2.2x… …would expand to 2.9x if Seafire executes on M&A… …which could add 43% pf to...
Redeye gives a short comment on today’s update on the approval process for Tesofensine in Mexico.
Redeye updates its estimates following Carasent’s Q1 report and comments on topics ranging from the ...
Redeye updates its estimates for 2022, following reviews of the quarterly report, the company’s prod...
